Abstract:CD19 antigen is a major target for human B cell malignancies. Many studies have shown that the antibodies recognizing this antigen hold clinical therapeutic potential, while CD19 antibody of mouse origin requires genetic engineering to reduce the potential side effects of the antibody for their clinical use. There are many clones of CD19 antibodies available with different subclasses of immunoglobulin. IgM type antibody holds a high affinity and high complement activating capacities facilitating the targeting efficacy when it is used in targeting therapy. However, engineering the murine IgM antibody into a functional humanized antibody remains a challenge. The aim of this study was to construct a chimeric antibody composed of a CD19 specific murine IgM antibody 2E8 single-chain antibody fragment (scFv) and human IgG1 Fc region, which was named 2E8scFv-Fc or Hm2E8b. The function and the biological activities of this engineered antibody were characterized using a variety of approaches including cellular, immunological, flow cytometric, and molecular biological approaches. After switching from IgM- to IgG-like type antibody, Hm2E8b retained full antigen-binding activity to membrane CD19 antigen as its parental antibody 2E8, and the immune effector function analysis revealed that it could mediate complement-dependent cytotoxicity (CDC) to kill the target cells via IgG1 Fc domain. The yield of the engineered antibody Hm2E8b in the supernatant was 13.3 μg/mL expressed and secreted in the CHO cell system, which reached the secretory quantity of a regular mouse hybridoma cells. Our conclusion is that the IgM type of CD19 mouse antibody can be successfully engineered into an IgG1 type human-mouse chimeric antibody with similar affinity and biological activity. The yield of the Hm2E8b expression and secretion in CHO cell system was adequate to facilitate further development for therapeutic purpose.

[Expression of GST-HAI-1 Fusion Protein and Development of Monoclonal Antibody Against Human Hepatocyte Growth Factor Activator Inhibitor 1].

Preparation and Identification of Monoclonal Antibody Against Human Testis Development Related Gene 1

A novel rabbit anti-hepatocyte growth factor monoclonal neutralizing antibody inhibits tumor growth in prostate cancer cells and mouse xenografts

Production and Application of Monoclonal Antibodies to GST

Expression and Function of Hepatocyte Growth Factor Activator Inhibitor Type 1

Expression,purification and preparation of monoclonal antibody of HCA518 protein

Development and Characterization of a Novel Fusion Protein of a Mutated Granulocyte Colony-Stimulating Factor and Human Serum Albumin in Pichia Pastoris.

[Construction of Recombinant GST-RCAS1 Fusion Gene and Its Expression in E. Coli].

Expression of Glutathione S-transferase Fusion Proteins of Human CYP1A1 and Preparation of Anti CYP1A1 Polyclonal Antibody

Hepatocyte Growth Factor Activator Inhibitor Type‑1 in Cancer: Advances and Perspectives (Review).

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Construction,expression and Characterization of Recombinant Fusion Protein HSA-PTH(1-34) in Pichia Pastoris

[Expression of recombinant human hemangiopoietin and preparation of its polyclonal antibody]

[Effect of HAI-1 Over-Expression on in Vitro Growth and Migration/motility of SW620 Cells].

Preparation and Identification of Monoclonal Antibodies Against Humanin

A humanized chimeric antibody Hai178 targeted to the β subunit of F1F0 ATP synthase

[Expression, purification and polyclonal antibody preparation of GST-Ccd1 fusion protein]

Characterization of an intracellular humanized single-chain antibody to matrix protein (M1) of H5N1 virus

Prokaryotic Expression,purification and Identification of GST-human S100A9 Fusion Protein

Generation and Characterization of Monoclonal Antibody Against Human PIK3IP1

Preparation and Characterization of Monoclonal Antibody Against Human Angiopoietin-Like Protein 2